This article is part of the supplement: Proceedings of the 11th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI): Basic, Epidemiologic, and Clinical Research .

Oral presentation

Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma

GM Clifford¹, M Rickenbach², S Franceschi¹ and the Swiss HIV Cohort Study

¹  International Agency for Research on Cancer, Lyon, France

²  Coordination and Data Center, Swiss HIV Cohort Study, Lausanne, Switzerland

corresponding author email

from 11th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI): Basic, Epidemiologic, and Clinical Research
Bethesda, MD, USA. 6–7 October 2008

Infectious Agents and Cancer 2009, 4(Suppl 2):O6doi:10.1186/1750-9378-4-S2-O6

The electronic version of this abstract is the complete one and can be found online at: http://www.infectagentscancer.com/content/4/S2/O6

Published:

17 June 2009

© 2009 Clifford et al; licensee BioMed Central Ltd.

Objective

To investigate HIV-related immunodeficiency as a risk factor for hepatocellular carcinoma (HCC) among persons infected with HIV, whilst controlling for the effect of frequent co-infection with hepatitis C and hepatitis B viruses.

Design

A case-control study nested in the Swiss HIV Cohort Study (SHCS).

Methods

Twenty-six HCC cases were identified in the SHCS or through linkage with Swiss Cancer Registries, and were individually matched to 251 controls by SHCS centre, gender, HIV-transmission category, age and year at enrolment. Odds ratios (OR) and corresponding confidence intervals (CI) were estimated by conditional logistic regression.

Results

All cases and 53 percent of controls (92% of controls among intravenous drug users [IDU]) were positive for hepatitis B superficial antigen (HBsAg) or antibodies against HCV (anti-HCV). HCC cases included 14 IDU (three positive for HBsAg, 13 for anti-HCV), and 12 men having sex with men (MSM)/heterosexual/others (11 positive for HBsAg, three for anti-HCV), revealing a strong relationship between HIV transmission route and hepatitis viral type. Latest CD4+ cell count was significantly associated with HCC (OR for lowest versus highest tertile = 4.26, 95% CI: 1.18–15.5). This effect was concentrated among MSM/heterosexual/others (OR = 18.2, 95% CI: 1.61–207) rather than IDU (OR = 1.79, 95% CI: 0.39–8.23). HAART use was not significantly associated with HCC risk (OR for ever versus never = 0.59, 95% CI: 0.18–1.91).

Conclusion

More than CD4+ cell counts increased the risk for HCC among persons infected with HIV, an effect that was particularly evident for HBV-related HCC arising in non-IDUs.

Have something to say? Post a comment on this article!